Chen Bihua
SEC insider (Form 3/4/5 filer). CIK 0001599214. Director & 10% Owner at BlossomHill Therapeutics, Inc. (BLSM) and 4 other issuers. 27 reported Form 4/5 transactions since Sep 2024; latest on Aug 10, 2026. Located in BOSTON, MA.
Companies Chen Bihua has filed insider reports for
- BlossomHill Therapeutics, Inc. (BLSM): Director, 10% Owner
- BridgeBio Oncology Therapeutics, Inc. (BBOT): Director, 10% Owner
- Helix Acquisition Corp. III (HLXC): Director, Officer, 10% Owner, Chairperson and CEO
- MoonLake Immunotherapeutics (MLTX)
- Biomea Fusion, Inc. (BMEA): Director, 10% Owner
Chen Bihua
CIK: 0001599214
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (27 total)
- Aug 10, 2026BLSM
BlossomHill Therapeutics, Inc.
PurchaseIndirect312.5K shares at avg. $16.00$5.0M - Aug 10, 2026BLSM
BlossomHill Therapeutics, Inc.
ConversionIndirect1.6M shares- - Aug 10, 2026BLSM
BlossomHill Therapeutics, Inc.
ConversionIndirect1.7M shares- - Aug 6, 2026BLSM
BlossomHill Therapeutics, Inc.
AwardDirectDirector Stock Option (Right to Buy)
23.9K shares- - Jul 1, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
OtherIndirect2.7M shares- - Jul 1, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
OtherIndirect1.7M shares- - Jul 1, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
OtherIndirect130.9K shares- - Jul 1, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
OtherIndirect4.5M shares- - Jun 16, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
31.7K shares- - Jan 26, 2026HLXC
Helix Acquisition Corp. III
AwardIndirect497.5K shares at avg. $10.00$5.0M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 10, 2026 |  BLSM BlossomHill Therapeutics, Inc. | Purchase | 312,500 | $16.00 | $5,000,000 | Indirect |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Conversion | 1,599,993 | - | $0 | Indirect |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Conversion | 1,701,541 | - | $0 | Indirect |
| Aug 6, 2026 | BLSM BlossomHill Therapeutics, Inc. | Award Director Stock Option (Right to Buy) | 23,904 | - | - | Direct |
| Jul 1, 2026 |  BBOT BridgeBio Oncology Therapeutics, Inc. | Other | 2,692,459 | - | $0 | Indirect |
| Jul 1, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | Other | 1,704,862 | - | $0 | Indirect |
| Jul 1, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | Other | 130,865 | - | $0 | Indirect |
| Jul 1, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | Other | 4,528,186 | - | $0 | Indirect |
| Jun 16, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | Award Stock Option (Right to Buy) | 31,675 | - | - | Direct |
| Jan 26, 2026 |  HLXC Helix Acquisition Corp. III | Award | 497,500 | $10.00 | $4,975,000 | Indirect |
1-10 of 27 transactions